#agamree
LightNews LightNews
dmdwarrior.com
Agamree recommended for NHS use in England 🎉

Elsewhere, Agamree was approved in China, making it the country’s first treatment for DMD.

#dmd #duchenne #bmd #becker #santhera #agamree #uk #vamorolone #england
Agamree recommended for NHS use in England Agamree recommended for NHS use in England Agamree recommended for NHS use in England Agamree recommended for NHS use in England
December 13, 2024 at 9:25 AM
dmdwarrior.com
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy 🎉

Source: www.santhera.com/assets/files...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #santhera #agamree #china #vamorolone
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
December 11, 2024 at 5:09 PM
drskorzy.bsky.social
Spent 2 yrs of my life doing bench research for this fucking horrible disease. Articles like this finally validate time of my life I thought wasted. www.biospace.com/article/fda-...
FDA Approves Third Duchenne Muscular Dystrophy Treatment in Nine Months
Duvyzat, which will be sold in the U.S. by ITF Therapeutics, joins a growing market that includes recently approved gene therapy Elevidys and corticosteroid Agamree.
www.biospace.com
March 23, 2024 at 12:17 AM
dmdwarrior.com
Vamorolone (Agamree) Approved in Scotland

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #agamree #vamorolone #santhera #scotland #uk #england
Vamorolone (Agamree) Approved in Scotland The Scottish Medicines Consortium (SMC) approved the Agamree (Vamorolone) for use by NHS Scotland. The medication vamorolone, also marketed under the brand name Agamree, has been approved by the Scottish Medicines Consortium (SMC) as a therapy option for Duchenne muscular dystrophy in patients four years of age and older in Scotland as of today, Monday, January 13 2025.
January 13, 2025 at 3:36 PM
deutsch.awp.news
Santhera schliesst Vertriebsabkommen mit Clinigen Group für DMD-Mittel Agamree

Santhera ist mit der Clinigen Group eine Liefer- und Vertriebsvereinbarung für seinen Wachstumsträger Agamree (Vamorolon) eingegangen. #Santhera #news

https://www.awp.ch/sharedarticles?articleid=-1994176054
January 6, 2025 at 7:17 AM
rengewkram.bsky.social
Naja, er läuft noch kurze Strecken, letzte Woche sogar 1x Ikea oben und unten mit Pausen und Kantinenstopp aber der Abbau ist real. Er bekommt Agamree anstatt Cortison. Dadurch wächst er schneller und das schaffen seine Muskeln nicht. Dazu diese verdammten Bauchschmerzen (Nebenwirkungen v. Agamree).
September 2, 2025 at 8:49 PM
dmdwarrior.com
Agamree to be sold in United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain starting in 2026

#agamree #vamorolone #uae #bahrain #oman #saudi_arabia #kuwait

👉 Read More: DMDWarrioR.com
Agamree to be sold in United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain starting in 2026 Santhera Pharmaceuticals announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.
August 19, 2025 at 7:39 AM
nmd4c.ca
Health Canada has approved AGAMREE® (vamorolone), the first treatment for #DMD in Canada. Our Network is proud to advance research, improve care, and support families affected by #Duchenne.
Read More → neuromuscularnetwork.ca?p=202191
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada - News - NMD4C
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
neuromuscularnetwork.ca
October 7, 2025 at 12:01 PM
rengewkram.bsky.social
Naja, es verläuft mit Medikamenten schon anders aber die Nebenwirkungen sind nicht zu übersehen. Osteoporose, Mondgesicht, Verhaltensauffälligkeiten…Mit Agamree haben wir die Osteoporose gegen Bauchschmerzen eingetauscht. Der Rest bleibt mehr oder weniger. Demnächst dann Givinostat. We will see…
September 3, 2025 at 7:24 AM
pharmacyphunquiz.bsky.social
The Drug brand name is A, Agamree (vamorolone), a corticosteroid indicated for Duchenne muscular dystrophy. Ambilobe, Fandriana, and Fenoavrivo are municipalities in the island nation of Madagascar. Thanks for playing the Name Game. Catch a different version tomorrow.
a red white and green flag is waving in the wind against a blue sky
ALT: a red white and green flag is waving in the wind against a blue sky
media.tenor.com
April 27, 2025 at 1:06 AM
ad-hoc-news.de.web.brid.gy
Santhera: Edison erwartet Cashflow-Break-even im Q3
Santhera Pharmaceuticals nähert sich der Gewinnzone: Analysten prognostizieren den operativen Durchbruch im Q3 2026 dank Agamree und der Nxera-Kooperation.
www.ad-hoc-news.de
August 25, 2026 at 1:07 AM
ad-hoc-news.de.web.brid.gy
Santhera: Break-even im dritten Quartal angepeilt
Santhera strebt im dritten Quartal den operativen Break-even an. Agamree-Umsätze verdoppeln sich, während die Expansion nach Zentralasien startet.
www.ad-hoc-news.de
August 2, 2026 at 12:37 PM
deutsch.awp.news
Santhera erweitert Vereinbarung mit Biomedica für Agamree in Zentralasien

Santhera Pharmaceuticals hat seine Vertriebsvereinbarung mit Biomedica aus dem Oktober 2025 für Agamree (Vamorolon) erweitert.

https://www.awp.ch/sharedarticles?articleid=-1975072562
July 13, 2026 at 5:47 AM
francais.awp.news
Santhera étend son accord avec Biomedica pour Agamree

https://www.awp.ch/sharedarticles?articleid=-1975072472
July 13, 2026 at 6:02 AM
salutedomani.bsky.social
Distrofia Muscolare di Duchenne (DMD): dati a 5 anni con vamorolone (AGAMREE*) mostrano un profilo di sicurezza migliorato con un’efficacia paragonabile ai corticosteroidi standard www.saluteh24.com/2025/11/04/d...
November 4, 2025 at 4:24 PM
trakyalife.bsky.social
İlaç Şirketi Gen ve Santhera Pharmaceuticals Anlaştı!

Gen İlaç ve Sağlık Ürünleri ile İsviçre merkezli Santhera Pharmaceuticals arasında Duchenne Muscular Dystrophy hastalığının tedavisinde kullanılan AGAMREE ürünün Türkiye'deki distribütörlüğü için anlaşma imzalandı. İlacın satışları 2026 yılının…
İlaç Şirketi Gen ve Santhera Pharmaceuticals Anlaştı!
Gen İlaç ve Sağlık Ürünleri ile İsviçre merkezli Santhera Pharmaceuticals arasında Duchenne Muscular Dystrophy hastalığının tedavisinde kullanılan AGAMREE ürünün Türkiye'deki distribütörlüğü için anlaşma imzalandı. İlacın satışları 2026 yılının ilk yarısında başlayacak. #haberler
www.trakyalife.com
August 13, 2025 at 8:05 AM
dmdwarrior.com
Agamree (vamorolone) will be Covered in Slovenia by the Slovenian Health Insurance Fund

The drug will be covered by the Slovenian Health Insurance Fund as of April 23, 2025.

#dmd #duchenne #agamree #vamorolone #Slovenia
Agamree (vamorolone) will be Covered in Slovenia by the Slovenian Health Insurance Fund - DMD Warrior
The Slovenian Health Insurance Institute (ZZZS) today added Agamree (vamorolone) to the list of drugs for the treatment of Duchenne muscular dystrophy in
dmdwarrior.com
April 24, 2025 at 9:12 AM
dmdwarrior.com
Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany

👉 Read More: dmdwarrior.com
Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany AGAMREE is the first product to receive an agreed federal price in Germany for the treatment of all DMD patients 4 years and older, and independent of genetic mutation.
February 14, 2025 at 8:46 AM
dmdwarrior.com
NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera

👉 Read More: dmdwarrior.com

#dmd #duchenne #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #agamree #vamorolone #santhera #NICE #uk #england #wales #northernireland
NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera AGAMREE (vamorolone) has been recommended for use in the National Health Service (NHS) in England, Wales, and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 and up by the National Institute for Health and Care Excellence (NICE), according to Santhera Pharmaceuticals.
January 16, 2025 at 8:24 AM
dmdwarrior.com
Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #agamree #vamorolone #santhera #Clinigen #clinigengroup
Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group "We look forward to working with Santhera to make AGAMREE available to patients globally on an unlicensed basis in those territories where it is not currently licensed or reimbursed. ” said Julie Gosper, Senior Vice President, Europe and Partner Markets at Clinigen. Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product is not otherwise commercially available. Santhera Pharmaceuticals and Clinigen Group announce that they have signed a Supply and Distribution Agreement for AGAMREE in countries where the product can currently not be commercially obtained via Santhera or one of its current distribution partners. The agreement will enable access to AGAMREE on a case-by-case basis for patients with Duchenne muscular dystrophy (DMD) in situations where the treating physician deems there to be no suitable alternatives and where regulations allow for it. This agreement allows Santhera to receive the majority share of revenue generated from the supply of product in these additional countries.
January 6, 2025 at 12:14 PM
sehmagazine.bsky.social
Malattie rare, risultati positivi a 5 anni per vamorolone in distrofia Duchenne 
Malattie rare, risultati positivi a 5 anni per vamorolone in distrofia Duchenne - S&H Magazine
(Adnkronos) - Sono positivi i risultati di un'analisi dei dati a lungo termine - comprese le prime valutazioni dello studio multicentrico in aperto Guardian, attualmente in corso - che valuta Agamree* (vamorolone) in pazienti affetti da distrofia muscolare di Duchenne (Dmd). Lo annuncia in una nota Santhera Pharmaceuticals, precisando che l'analisi ha incluso pazienti mai
www.shmag.it
November 4, 2025 at 4:08 PM
zalpergungor.bsky.social
#GENIL, İsviçre merkezli Santhera Pharmaceuticals ile AGAMREE* (vamorolone) ilacının Türkiye’deki münhasır distribütörlüğü için anlaşma imzaladı. İlaç 4+ yaş DMD hastalarında kullanılacak. Satışlar 2026’nın ilk yarısında başlayacak.
#BIST #BIST100
August 13, 2025 at 2:12 PM
vagus-trainer.bsky.social
www.globenewswire.com/de/news-rele...
Santhera gibt die Zulassung von AGAMREE® (Vamorolon) in Kanada zur Behandlung von Duchenne-Muskeldystrophie bekannt
Health Canada hat AGAMREE für die Behandlung von Duchenne-Muskeldystrophie bei Patienten ab 4 Jahren zugelassenMit dieser Zulassung ist AGAMREE das erste...
www.globenewswire.com
October 3, 2025 at 8:05 AM
francais.awp.news
Santhera: Agamree présente un effet anti-inflammatoire

https://www.awp.ch/sharedarticles?articleid=-1975395662
July 1, 2026 at 6:07 AM